Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo

ObjectiveMalignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM in vitro and in vivo.MethodsWe established sever...

Full description

Bibliographic Details
Main Authors: Zhi-Ran Yang, Zhi-Gao Chen, Xue-Mei Du, Yan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.585079/full
id doaj-6bd3049099ab435f963912d84afa04e0
record_format Article
spelling doaj-6bd3049099ab435f963912d84afa04e02020-12-08T08:33:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-12-011010.3389/fonc.2020.585079585079Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In VivoZhi-Ran Yang0Zhi-Gao Chen1Xue-Mei Du2Yan Li3Yan Li4Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Research, Thorgene Co., Ltd., Beijing, ChinaDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaObjectiveMalignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM in vitro and in vivo.MethodsWe established several patient-derived xenograft (PDX) models and primary cell lines of MPM. The cell lines were used to study the effects of apatinib on proliferation, cell cycle, migration, and apoptosis by CCK8, flow cytometry, wound-healing, Transwell, DAPI staining, and caspase-3 assays, respectively. For in vivo study, apatinib was delivered by gastric gavage into PDX models, and then efficacy and toxicity were determined by experimental peritoneal cancer index (ePCI) score and pathological examinations.ResultsOur results showed that apatinib significantly inhibited the proliferation and migration of MPM cells in vitro and induced cell cycle arrest. Studies on PDX models concurred that apatinib effectively suppressed subphrenic and liver invasions of nude mice. Moreover, histopathological analysis found that lymphocyte infiltration, coagulation necrosis and eosinophilic cell fragments were detected in tumor tissues after apatinib treatment. Apatinib showed no obvious effects on body mass of models and did not affect function of important organs, except for occasional focal lymphoid infiltration of liver (16.7%) and cardiac muscle (16.7%).ConclusionsWe successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM in vitro and in vivo study.https://www.frontiersin.org/articles/10.3389/fonc.2020.585079/fullmalignant peritoneal mesotheliomapatient-derived xenograft modelprimary cell linetoxicityapatinib
collection DOAJ
language English
format Article
sources DOAJ
author Zhi-Ran Yang
Zhi-Gao Chen
Xue-Mei Du
Yan Li
Yan Li
spellingShingle Zhi-Ran Yang
Zhi-Gao Chen
Xue-Mei Du
Yan Li
Yan Li
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
Frontiers in Oncology
malignant peritoneal mesothelioma
patient-derived xenograft model
primary cell line
toxicity
apatinib
author_facet Zhi-Ran Yang
Zhi-Gao Chen
Xue-Mei Du
Yan Li
Yan Li
author_sort Zhi-Ran Yang
title Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
title_short Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
title_full Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
title_fullStr Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
title_full_unstemmed Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
title_sort apatinib mesylate inhibits the proliferation and metastasis of epithelioid malignant peritoneal mesothelioma in vitro and in vivo
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2020-12-01
description ObjectiveMalignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM in vitro and in vivo.MethodsWe established several patient-derived xenograft (PDX) models and primary cell lines of MPM. The cell lines were used to study the effects of apatinib on proliferation, cell cycle, migration, and apoptosis by CCK8, flow cytometry, wound-healing, Transwell, DAPI staining, and caspase-3 assays, respectively. For in vivo study, apatinib was delivered by gastric gavage into PDX models, and then efficacy and toxicity were determined by experimental peritoneal cancer index (ePCI) score and pathological examinations.ResultsOur results showed that apatinib significantly inhibited the proliferation and migration of MPM cells in vitro and induced cell cycle arrest. Studies on PDX models concurred that apatinib effectively suppressed subphrenic and liver invasions of nude mice. Moreover, histopathological analysis found that lymphocyte infiltration, coagulation necrosis and eosinophilic cell fragments were detected in tumor tissues after apatinib treatment. Apatinib showed no obvious effects on body mass of models and did not affect function of important organs, except for occasional focal lymphoid infiltration of liver (16.7%) and cardiac muscle (16.7%).ConclusionsWe successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM in vitro and in vivo study.
topic malignant peritoneal mesothelioma
patient-derived xenograft model
primary cell line
toxicity
apatinib
url https://www.frontiersin.org/articles/10.3389/fonc.2020.585079/full
work_keys_str_mv AT zhiranyang apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo
AT zhigaochen apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo
AT xuemeidu apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo
AT yanli apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo
AT yanli apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo
_version_ 1724390957275676672